Video: How To Efficiently Patch A Medtech Regulatory System ‘Set Up To Fail’

“Hindsight is a wonderful thing, but foresight is better.”

Centralization and rationalization of the EU’s medtech rules are critical, particularly for conformity assessment and clinical evidence. Hear the views of Tom Melvin and Erik Vollebregt first-hand in a new in-depth interview on regulatory problems and opportunities.

Vodcast: How To Efficiently Patch A Medtech Regulatory System ‘Set Up To Fail’
Building Onto The EU's Medtech Regulations To Finish A Job Started But Not Completed

In this video interview with Medtech Insight, clinician and academic Tom Melvin, and legal medtech expert Erik Vollebregt expose the underlying regulatory factors that are undermining medical device safety efforts and damaging continued availability of medical devices in the EU.

Their strong opinions accord over what is now needed to fix the EU’s problematic medtech regulatory system.

Neither expert shy away from giving strong opinions about elements that urgently need correcting within the system.

But they also offer solutions that should be relatively easy to accommodate within the current EU rules, including introducing more reproducibility of efforts within the system to make it more efficient.

Deep Dive Into The Challenges

Topics covered during the interview include: role of competent authorities, notified bodies and expert panels; centralized regulatory control in the EU; clinical evidence; clinical standardization; “over-proceduralizing” of regulations; the regulation of high-risk devices versus other devices; creating EU-wide regulatory rationalization and efficiency; and the EU’s role in international harmonization.

Melvin, as associate professor of Medical Device Regulatory Affairs at Trinity College Dublin, gives particularly pertinent insights related to historic regulatory examples, including what has happened with medicines and how the US medtech system has evolved. And as a former clinician, he delivers valuable insights into the challenges that clinicians experience with medical devices on a day-to-day basis.

Vollebregt, a life sciences specialist lawyer and medtech regulatory expert at Axon Lawyers in the Netherlands, is at the forefront of promoting medtech regulatory change, having in summer 2024 helped draft the initiative for amendments to the MDR developed by MEP Peter Liese. (Also see "How The European Parliament Seeks To Amend The MDR: A Step-By-Step Guide" - Medtech Insight, 4 June, 2024.)

The quotes below offer highlights of the conversation and an indication of the topics covered and approach taken. But to do justice to the depth of this discussion featuring two of the EU’s most impactful regulatory voices on the fundamental challenges and needs of the EU regulatory system, readers can access the whole video interview via the link above.

Moreover, to help navigate your way around the interview, timestamps are provided alongside the quotes.

More from Europe

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

More from Geography

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.